Boston Scientific announced Friday the launch and first implants of its Energen and Punctua cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators in Europe and other markets. They are the world's smallest and thinnest high-energy devices to treat heart failure and sudden cardiac death, according to a company statement. Boston Scientific received CE Mark approval for the devices last October and is hoping for FDA's OK for the devices later this year or early next. Boston Scientific statement